Deep periprosthetic infection after shoulder arthroplasty is a devastating complication. In 2011, there were approximately 65,000 shoulder arthroplasties performed in the United States,[@bib0035], [@bib0090] and the volume of this procedure is expected to continue to grow.[@bib0030], [@bib0045] As a result, the number of revisions due to failures is also anticipated to increase.[@bib0030], [@bib0100] The overall estimated rate of deep infection after shoulder arthroplasty is approximately 1%.[@bib0080] Taking into account the rising number of shoulder arthroplasties being performed, the cost of managing the infected shoulder arthroplasty is expected to grow as well.

The financial burden associated with the treatment of periprosthetic hip and knee infections has been well-analyzed in the literature.[@bib0025], [@bib0040], [@bib0055], [@bib0065], [@bib0070], [@bib0105] It has been shown that the cost of revisions for periprosthetic hip and knee infections in the United States rose from \$320 million to 566 million between 2001 and 2009.[@bib0055] By 2020, this is expected to be around \$1.62 billion.[@bib0055] The financial burden associated with the treatment of an infected shoulder arthroplasty is likewise expected to be substantial.[@bib0080] The characteristics of periprosthetic shoulder infections are unlike those of the hip and knee, and previous reports suggest that they have a higher morbidity and costs compared with periprosthetic infections of other joints.[@bib0020], [@bib0075]

In North America, two-stage reimplantation is the most common treatment strategy used for the infected shoulder arthroplasty. To our knowledge, there is limited available information in the specific costs of treating a deep periprosthetic shoulder infection. The purpose of this study was to estimate the hospital cost of two-stage reimplantation for the treatment of deep infection after shoulder arthroplasty as compared to the cost of an uncomplicated primary shoulder arthroplasty.

Materials and methods {#s0010}
=====================

Study cohort {#s0015}
------------

This study was performed after approval from our institutional review board (IRB). Our institutional joint registry database[@bib0015] was utilized to identify all patients who underwent primary shoulder arthroplasty and all patients who underwent two-stage reimplantation for a periprosthetic shoulder joint infection between 2003 and 2012. The study cohort included 2953 primary procedures performed in 2589 patients, and 57 two-stage reimplantation procedures performed in 56 patients.

In the primary arthroplasty group, there were 1575 female patients (53%) and 1378 male patients (47%), with mean body mass index (BMI) of 30 ± 6 kg/m^2^, and mean age of 68.1 ± 12.3 years. The types of procedures performed in this group included an anatomic (non-reverse) total shoulder arthroplasty (a-TSA) in 1608 (55%) shoulders, a reverse shoulder arthroplasty (r-TSA) in 837 (28%) shoulders, and a hemiarthroplasty (HA) in 508 (17%) shoulders ([Table I](#t0010){ref-type="table"}).Table IDescription of the study cohortTable IVariablePrimary shoulder arthroplastyTwo-stage shoulder arthroplasty reimplantationa-TSAr-TSAHAOverall[\*](#tn0010){ref-type="table-fn"}a-TSAr-TSAHAOverallPatients138478648325893223156Shoulders1608(54.5%)837(28.3%)508(17.2%)2953(100.0%)33(58.0%)23(40.0%)1(2.0%)57(100.0%)Female8084992681575(53%)79117(30%)Male8003382401378(47%)2614--40(70%)Mean age67.1(±11.5)72.9(±9.0)63.6(±16.5)68.1(±12.3)61.1(±10.2)65.8(±10.0)5762.9(±10.2)Mean BMI(±SD)31.0(±6.0)30.0(±6.0)30.0(±7.0)30.0(±6.0)32.0(±7.0)31.0(±6.0)22.031.0(±7.0)Median LOS in days(IQR)2(1to3)2(1to3)2(1to3)2(1to3)6(4to8)5(3to6)35(4to7)[^1][^2]

In the two-stage reimplantation group, there were 17 female patients (30%) and 40 male patients (70%) with mean BMI of 31 ± 7 kg/m^2^ and mean age of 62.9 ± 10.2 years. At the time of reimplantation, the types of procedures performed included an a-TSA in 33 (58%) shoulders, a r-TSA in 23 (40%), and a HA in one (2%) shoulder.

Cost data {#s0020}
---------

Cost data for each hospitalization episode were obtained from an institutional research database that includes line item details (date, type, frequency, and billed charge) and standardized, inflation-adjusted costs for all services and procedures billed to patients treated at our institution.[@bib0010], [@bib0050], [@bib0060], [@bib0065] Given the discrepancies between billed charges and true resource use, bottom-up micro-costing valuation techniques were employed to generate standard inflation-adjusted estimates of the costs in constant dollars.[@bib0010], [@bib0050], [@bib0060], [@bib0065] As described previously,[@bib0010], [@bib0050], [@bib0060], [@bib0065], [@bib0085] the overall utilization and its value are grouped into Part A (e.g. room and board, radiology, physical therapy, implants, other supplies, etc.) and Part B (i.e., professional costs, examinations and consultations, diagnostic and therapeutic procedures). Costs were adjusted to nationally representative unit costs in 2013 inflation-adjusted dollars. Additionally, costs related to each hospital stay were categorized further into room and board, pharmacy and medications, laboratory and pathology tests, and implants.[@bib0010], [@bib0050], [@bib0060], [@bib0065], [@bib0085]

Statistical analyses {#s0025}
--------------------

The total direct medical costs during hospitalization were compared between the two study groups, primary shoulder arthroplasty (n = 2953 shoulders) and two stage reimplantation (n = 57 shoulders). For primary arthroplasty procedures, costs were estimated per hospital episode. For patients who had two-stage shoulder reimplantation procedures, costs from the 2 hospitalization episodes were combined and costs were expressed as costs per shoulder. Thus, the cost estimates for two-stage procedures are the total from 2 hospitalizations. As appropriate, data were expressed as means with standard deviations (SD), means with 95% confidence intervals (95% CI), medians with interquartile range (IQR) or frequencies with percentages. The statistical significance was set at a p-value of \<0.05.

Results {#s0030}
=======

Overall cost {#s0035}
------------

The mean overall hospital cost (per shoulder) for the treatment of patients with two-stage shoulder arthroplasty reimplantation was \$35,824 (95%CI: \$33,363 to 38,285) and was more than double (approximately 2.2-fold higher) compared to a mean of \$16,068 (95%CI: \$15,823 to \$16,314) for the treatment with primary shoulder arthroplasty (p \< 0.001).

The cost difference between primary and two-stage reimplantation groups was evident for both Part A (hospital services) and Part B (professional services) costs. For Part A (hospital services), the costs were significantly higher for two-stage reimplantation procedures with a mean of \$29,851 (95%CI: \$27,741 to \$31,960) compared to \$13,508 (95%CI: \$13,302 to \$13,715) for primary shoulder arthroplasty (p \< 0.001). For Part B (professional costs), the mean costs were also significantly higher for treating patients with two-stage reimplantation (mean: \$5973; 95%CI: \$5493 to \$6453) compared to patients having primary arthroplasty (mean: \$2560; 95%CI: \$2512 to \$2608) (p \< 0.001) ([Table II](#t0015){ref-type="table"}).Table IITotal direct medical costs according to type of shoulder arthroplasty procedure[\*](#tn0015){ref-type="table-fn"}Table IIVariablePrimary shoulder arthroplastyTwo-stage shoulder arthroplasty reimplantationa-TSA\
N = 1608r-TSA\
N = 837HA\
N = 508Overall\
N = 2953a-TSA\
N = 33r-TSA\
N = 23HA\
N = 1Overall\
N = 57Mean (95% CI)\$14,567 (14,312 to 14,822)\$18,956 (18,591 to 19,322)\$16,062 (15,129 to 16,995)\$16,068 (15,823 to 16,314)\$34,732 (31,027 to 38,437)\$37,675 (34,487 to 40,862)\$28,188\$35,824 (33,363 to 38,285)Median (IQR)\$14,095 (12,844 to 15,403)\$18,200 (16,890 to 19,878)\$12,966 (11,576 to 15,987)\$14,863 (13,098 to 17,596)\$32,758 (27,028 to 36,703)\$36,579 (32,385 to 41,864)\$34,558 (29,722 to 39,376)[^3]

Length of stay and cost categories {#s0040}
----------------------------------

For the two-stage reimplantation group, patients were hospitalized twice, leading to a significantly longer length of stay in the hospital (median: 5 days; IQR: 4 to 7 days) compared to patients who had undergone primary shoulder arthroplasty (median: 2 days; IQR: 1 to 3 days) (p \< 0.001). Extended hospital stay (2 hospitalizations) for the two-stage reimplantation resulted in a significantly higher costs for room and board utilization with a mean of \$6894 (95% CI: 5926 to 7861) compared to \$2547 (95% CI: 2450 to 2644) for the primary arthroplasties. The costs associated with two-stage reimplantation were higher in all aspects of care, including implant costs. Costs of pharmacy and medications, costs of laboratory and pathology tests, and costs of implants were also significantly higher in the two-stage reimplantation compared to the primary arthroplasty group ([Table III](#t0020){ref-type="table"}).Table IIIComponents of direct medical costs according to type of shoulder arthroplasty procedure[\*](#tn0020){ref-type="table-fn"}Table IIIVariablePrimary shoulder arthroplasty (N = 2953)Two-stage shoulder arthroplasty reimplantation (N = 57)Room and board\$2547 (2450 to 2644)\$6894 (5926 to 7861)Pharmacy and medications\$656 (621 to 690)\$2106 (1842 to 2369)Laboratory and pathology tests\$337 (304 to 370)\$2352 (1931 to 2774)Implants\$4466 (4384 to 4548)\$6804 (5600 to 8008)[^4]

Discussion {#s0045}
==========

Joint replacement has been proven to be a highly cost-effective surgical intervention. However, when complications happen, they can lead to increasing costs very quickly. Over the last few years, the volume of shoulder arthroplasty performed worldwide has increased substantially.[@bib0030] The number of individuals requiring surgical treatment of a deep periprosthetic infection will continue to increase proportionally. The financial implications of managing deep infection after shoulder arthroplasty with a two-stage reimplantation, thoroughly investigated in this study, more than double the cost of an uncomplicated primary shoulder arthroplasty. Costs are increased across all categories, including room and board utilization, pharmacy, medications, laboratory and pathology studies, as well as implants.

The cost of dealing with deep infection after hip or knee arthroplasty has been thoroughly investigated.[@bib0025], [@bib0040], [@bib0055], [@bib0065], [@bib0070], [@bib0105] Bozic and Ries[@bib0025] reported that two-stage hip reimplantation for periprosthetic infection was associated with longer operative time, greater blood loss, and more complications compared to both primary hip replacement and revision for aseptic loosening. Two-stage reimplantation also leads to a higher number of hospitalizations, hospital stay, reoperations and outpatient clinic visits during the first year after surgery. Mean costs were significantly greater for two-stage reimplantation compared to both revision for aseptic loosening and primary arthroplasty in terms of both hospital costs (\$96,166 versus \$34,866 and \$21,654, respectively) and outpatient charges (\$48,348 versus \$16,411 and \$8519 respectively). Similar data have been reported for deep infection after knee arthroplasty. In the study by Kapadia et al[@bib0040] two-stage reimplantation was associated with longer length of stay, more readmissions, more outpatient clinic visits, and greater mean annual costs (\$116,383 versus \$28,249) compared to matched cohort of patients who had primary knee replacement.

There are less published studies regarding the cost of managing infection after shoulder arthroplasty. Schairer et al[@bib0095] analyzed 90-day readmission data after shoulder arthroplasty as collected in a state inpatient database; the mean overall cost of readmission was \$10,947, with infection being the most common reason for readmission. Padegimas et al[@bib0080] analyzed the national economic burden of periprosthetic infection after primary shoulder arthroplasty in the United States, and found approximate median hospital costs of \$17,000 for the treatment of periprosthetic infection as compared to \$16,000, \$14,000, and \$20,000 for primary total shoulder arthroplasty, hemiarthroplasty, and reverse arthroplasty, respectively. Interestingly, costs reported by these authors were inferior than costs reported in our study; this is likely due to the fact that a study based on the Nationwide Inpatient Sample (NIS) database using ICD-9 codes may have dialed to capture the second-stage for shoulders treated with a two-stage reimplantation.

Our study presents a number of weaknesses. First, cost data were limited to direct medical costs; we did not include outpatient costs, antibiotic treatment in between stages, physical therapy, extended care facility admissions, readmissions and reoperations after the second stage, days missed from work, or disability. Second, cost analyses were normalized to 2013 inflation-adjusted value, possibly inflating the costs applied over the entire study duration. Third, we did not analyze the impact of obesity and other comorbidities on cost. Finally, the utilization patterns in our institution may not reflect other practice patterns; thus, our results may not be generalizable to other practices.

Our study also presents a number of strengths. Our study cohort was large and obtained from a total joint registry[@bib0015] that includes prospectively collected data from a high volume tertiary care center. Thus, it avoids potential pitfalls associated with other data resources that may provide more incomplete information, such as the NIS data. In addition, we employed a robust cost methodology that estimated standardized costs applied to line item details of services, rather than simply relying on charges or average costs,[@bib0010], [@bib0050], [@bib0060], [@bib0065] and we were able to capture items that are otherwise difficult to obtain through NIS data, such as professional services, consultations and other ancillary services.

Conclusion {#s0050}
==========

In conclusion, the management of periprosthetic infection after shoulder replacement is a costly procedure with direct medical hospital costs at least two times higher than the primary shoulder arthroplasty procedures. Efforts toward preventing infection after shoulder arthroplasty will not only decrease overall patient morbidity but also lead to substantial financial savings and improve resource utilization.
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[^1]: *LOS*, length of hospital stay; *BMI*, body mass index.

[^2]: Sixty-four patients had multiple surgery types.

[^3]: Costs were presented as means with 95% confidence intervals.

[^4]: Costs were presented as means with 95% confidence intervals.
